B46.4
Disseminated mucormycosis
Clinical Classification Guidelines
Inclusion Terms
- Generalized mucormycosis
Medical Intelligence & Overview
Disseminated mucormycosis, classified under ICD-10 Code B46.4, is a serious fungal infection caused by mold belonging to the Mucorales order. This condition is characterized by widespread infection that can affect multiple organs and tissues throughout the body. It is considered a medical emergency, particularly in individuals with weakened immune systems. Recognizing the features of disseminated mucormycosis is crucial for prompt diagnosis and management, although treatment can be complex and requires specialized medical care.
Causes & Symptoms
Clinical Causes: Inhalation of spores from Mucorales fungi, especially in environments with decaying organic matter. Spread from a localized mucormycosis infection, such as sinus or skin infections. Underlying health conditions that impair the immune response, allowing fungi to invade multiple organ systems.
Key Symptoms: Fever and chills that persist or worsen over time. Pain or swelling in affected areas, such as the sinuses, lungs, or skin. Respiratory symptoms like shortness of breath, cough, or chest pain. Skin lesions that may be necrotic or blackened due to tissue death. Signs of organ dysfunction depending on the sites involved, including neurological symptoms if the brain is affected. General malaise, fatigue, and weight loss in systemic cases.
Diagnostic & Treatment
Diagnosis Path: The diagnosis of disseminated mucormycosis involves a combination of clinical assessment and laboratory investigations. Imaging studies, such as CT scans or MRIs, help identify the extent and sites of infection. Confirmatory diagnosis typically requires histopathological examination of tissue biopsies, where characteristic broad, ribbon-like, non-septate hyphae are observed. Fungal cultures and molecular tests may also assist in identifying the specific mold species involved. Because of the aggressive nature of this infection, prompt diagnostic measures are essential for early intervention.
Treatment Protocols: Treatment strategies focus on reversing underlying immunosuppression, administering antifungal medications, and surgical removal of infected tissues when necessary. The main antifungal agents used include amphotericin B and its lipid formulations, which are often administered intravenously. Newer antifungal drugs, such as posaconazole or isavuconazole, may be considered in some cases. Surgical intervention helps remove necrotic tissues to reduce fungal burden and improve drug penetration. Managing comorbidities, such as controlling blood sugar levels in diabetics, is an important aspect of care. Due to the potential severity, multidisciplinary teams are typically involved in treatment planning and execution.
Clinical Advice & FAQs
Billing Guidance
Is B46.4 a billable ICD-10 code?
Yes, B46.4 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report B46.4?
Clinical documentation must specify the nature of Disseminated mucormycosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
